DK0573562T3 - Dihydroquinolin NMDA-antagonister - Google Patents

Dihydroquinolin NMDA-antagonister

Info

Publication number
DK0573562T3
DK0573562T3 DK92907466.4T DK92907466T DK0573562T3 DK 0573562 T3 DK0573562 T3 DK 0573562T3 DK 92907466 T DK92907466 T DK 92907466T DK 0573562 T3 DK0573562 T3 DK 0573562T3
Authority
DK
Denmark
Prior art keywords
dihydroquinoline
nmda antagonists
nmda
antagonists
sulfanimide
Prior art date
Application number
DK92907466.4T
Other languages
English (en)
Inventor
Bruce M Baron
Boyd L Harrison
David M Stemerick
Ian A Mcdonald
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Application granted granted Critical
Publication of DK0573562T3 publication Critical patent/DK0573562T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK92907466.4T 1991-02-27 1992-02-11 Dihydroquinolin NMDA-antagonister DK0573562T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66178091A 1991-02-27 1991-02-27
US70000491A 1991-05-14 1991-05-14

Publications (1)

Publication Number Publication Date
DK0573562T3 true DK0573562T3 (da) 1996-05-13

Family

ID=27098383

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92907466.4T DK0573562T3 (da) 1991-02-27 1992-02-11 Dihydroquinolin NMDA-antagonister

Country Status (14)

Country Link
EP (1) EP0573562B1 (da)
JP (1) JP3465794B2 (da)
KR (1) KR100224045B1 (da)
AT (1) ATE137225T1 (da)
AU (1) AU660969B2 (da)
CA (1) CA2104297C (da)
DE (1) DE69210229T2 (da)
DK (1) DK0573562T3 (da)
ES (1) ES2089511T3 (da)
FI (1) FI103202B (da)
GR (1) GR3019772T3 (da)
HU (1) HU217425B (da)
NO (1) NO180485C (da)
WO (1) WO1992015565A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists
ATE404201T1 (de) * 1992-06-22 2008-08-15 Univ California Glycinrezeptorantagonisten und ihre verwendung
US5475007A (en) * 1993-05-28 1995-12-12 The Regents Of The University Of California 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
DE69416324T2 (de) * 1993-11-29 1999-06-10 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Heterocyclische benzolsulfonyliminderivate als inhibitoren der il-1 wirkung
ES2131297T3 (es) * 1993-11-29 1999-07-16 Merrell Pharma Inc Nuevos derivados de bencenosulfonilamina como inhibidores de la accion il-1.
CA2788656A1 (en) 2010-02-16 2011-08-25 Pfizer Inc. (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719102D0 (en) * 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
IL93610A0 (en) * 1989-03-08 1990-12-23 Merck Sharp & Dohme Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them
ZA903588B (en) * 1989-05-16 1991-02-27 Merrell Dow Pharma Excitatory amino acid antagonists

Also Published As

Publication number Publication date
WO1992015565A1 (en) 1992-09-17
AU660969B2 (en) 1995-07-13
DE69210229D1 (de) 1996-05-30
JP3465794B2 (ja) 2003-11-10
DE69210229T2 (de) 1996-11-14
ATE137225T1 (de) 1996-05-15
HU9302433D0 (en) 1993-11-29
NO933042D0 (no) 1993-08-26
NO180485C (no) 1997-04-30
CA2104297A1 (en) 1992-08-28
FI103202B1 (fi) 1999-05-14
HUT67301A (en) 1995-03-28
GR3019772T3 (en) 1996-07-31
NO180485B (no) 1997-01-20
FI933762A (fi) 1993-08-26
AU1532092A (en) 1992-10-06
EP0573562A1 (en) 1993-12-15
FI933762A0 (fi) 1993-08-26
JPH06505746A (ja) 1994-06-30
HU217425B (hu) 2000-01-28
KR100224045B1 (ko) 1999-10-15
EP0573562B1 (en) 1996-04-24
FI103202B (fi) 1999-05-14
ES2089511T3 (es) 1996-10-01
CA2104297C (en) 2003-05-27
KR930703257A (ko) 1993-11-29
NO933042L (no) 1993-08-26

Similar Documents

Publication Publication Date Title
NO914300D0 (no) Fremgangsmaate for fremstilling av 3-amidoindolderivater
FI945434A (fi) 4-markatpoasetyyliamino/2/bentsatsepinoni (3) johdannaisia ja niiden käyttö enkefalinaasi-inhibiittoreina
NO930035D0 (no) Eksitatoriske aminosyreantagonister
ES2072607T3 (es) Derivados 3 indolil tioacetato.
DE69230224D1 (de) Potenzierung von nmda-antagonisten
DK0573562T3 (da) Dihydroquinolin NMDA-antagonister
DK0532629T3 (da) 1-Piperidinyl-alkanoylarylsulfonamid-derivater
ATE131172T1 (de) Heterocyclische nmda antagonisten.
NO920022L (no) Umettede hydroksyalkylkinolinsyrer som leukotrienantagonister